---
title: "PIII: Q2 2026 saw robust EBITDA growth, improved cost trends, and a raised full-year outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295456266.md"
description: "Q2 2026 delivered strong financial results with $54M adjusted EBITDA and improved medical cost trends, driven by operational execution, payer settlements, and expanded clinical programs. Full-year EBITDA guidance was raised to $80–$110M, reflecting confidence in durable earnings.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-10T21:53:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295456266.md)
  - [en](https://longbridge.com/en/news/295456266.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295456266.md)
generator: "portal-rs"
---

# PIII: Q2 2026 saw robust EBITDA growth, improved cost trends, and a raised full-year outlook

Q2 2026 delivered strong financial results with $54M adjusted EBITDA and improved medical cost trends, driven by operational execution, payer settlements, and expanded clinical programs. Full-year EBITDA guidance was raised to $80–$110M, reflecting confidence in durable earnings.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PIII.US](https://longbridge.com/en/quote/PIII.US.md)
- [PIIIW.US](https://longbridge.com/en/quote/PIIIW.US.md)

## Related News & Research

- [P3 Health Partners Secures Up To $70 Million CPF Financing; Updates Governance and Registration Rights](https://longbridge.com/en/news/298767691.md)
- [P3 Health Partners agrees to sell up to $70 million of preferred stock units with warrants in private placement](https://longbridge.com/en/news/298766765.md)
- [UNFI: Guidance for renewed growth in H2 2027 is backed by operational gains and a focused market strategy](https://longbridge.com/en/news/299055727.md)
- [CER: Revenue and EBITDA margin will miss forecasts due to order delays, but outlook remains robust](https://longbridge.com/en/news/298872423.md)
- [MNY: Adjusted EBITDA loss narrowed and new high-margin products launched, supporting profitable growth](https://longbridge.com/en/news/298737733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**